Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.43 |
| ▸ | MMP13 | P45452 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LPL | P06858 | 5/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20867850 | 0.99 | MMP13 (0.45) | HPGDMMP13CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL26340070 | 0.79 | HPGD (0.66) | HPGDMMP13CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL3583064 | 0.77 | MAPT (0.64) | HPGDMMP13CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL4381940 | 0.72 | HPGD (0.49) | HPGDMMP13CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL20868170 | 0.71 | PLA2G7 (0.53) | CXCR2MEN1KMT2A | |
| SCHEMBL20867851 | 0.71 | PLA2G7 (0.54) | CXCR2 | |
| SCHEMBL20868287 | 0.67 | PLA2G7 (0.40) | HPGDMMP13CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL9878956 | 0.66 | ALDH1A1 (0.50) | HPGDMAPTLMNAKMT2ATSHR | |
| SCHEMBL4375736 | 0.66 | ALDH1A1 (0.53) | HPGDMAPTLMNATP53MEN1 | |
| SCHEMBL20868160 | 0.66 | GAA (0.47) | HPGDMMP13CYP2C9MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11583596-B2 | Radiolabeled Darapladib and analogs thereof and their use as imaging compounds | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2023-02-21 | — | — | US | disclosed |
| EP-3687980-B1 | RADIOLABELED DARAPLADIB, ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS | INST NAT SANTE RECH MED (FR) | 2022-01-19 | — | — | EP | disclosed |
| US-20200276337-A1 | RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2020-09-03 | — | — | US | disclosed |
| WO-2019063634-A1 | RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11583596-B2 | Radiolabeled Darapladib and analogs thereof and their use as imaging compounds | PLA2G4B, PLA2G1B, PLA2G12B | HPGD 434/4885MMP13 964/4885CYP1A2 2886/4885 |
| US-20200276337-A1 | RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS | PLA2G4B, PLA2G1B, PLA2G12B | HPGD 434/4885MMP13 964/4885CYP1A2 2886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.